Growing Acceptance of Medicinal Cannabis to Boost the CBD Hemp Oil Market

 

The global CBD hemp oil market is experiencing significant growth, driven by increasing awareness of cannabidiol (CBD)-based products, rising healthcare expenditure, and growing demand for alternative therapeutic solutions. The market was valued at more than US$ 950 million in 2017 and was projected to surpass US$ 2.5 billion by 2026, expanding at a compound annual growth rate (CAGR) of over 11% during 2018–2026. Growing interest in managing chronic pain, sleep disorders, stress, and neurological conditions has contributed to the increasing adoption of CBD hemp oil across healthcare and wellness applications.

Rising Demand for CBD Hemp Oil in Healthcare Applications

CBD hemp oil is a plant-derived product containing cannabidiol, a non-intoxicating cannabinoid found in cannabis and hemp plants. It has attracted considerable attention from researchers, healthcare professionals, and consumers because of its potential therapeutic applications. Unlike tetrahydrocannabinol (THC), CBD does not produce the characteristic psychoactive effects associated with cannabis.

Increasing prevalence of chronic conditions, including cancer, diabetes, multiple sclerosis, and neurological disorders, has encouraged interest in CBD-based products. Furthermore, growing awareness of alternative approaches to managing stress, depression, inflammation, and chronic pain is supporting market expansion.

Technological advancements and product innovation are also creating new growth opportunities. CBD hemp oil is increasingly available in different formulations, including tinctures, sprays, capsules, topical applications, and vape products. These developments are improving product accessibility and offering consumers greater flexibility.

Market Segmentation and Emerging Opportunities

Based on product type, the global CBD hemp oil market is segmented into hemp-based and marijuana-based products. The hemp-based segment accounted for a significant revenue share in 2017, supported by increasing availability and growing commercial cultivation of industrial hemp. Meanwhile, the marijuana-based segment was expected to experience considerable growth as medicinal cannabis gained wider acceptance.

By application, the market includes neurological pain management and other therapeutic applications. Growing interest in CBD-based solutions for neurological pain and related conditions is expected to support demand among healthcare providers and individual consumers.

Based on distribution channel, the market is categorized into hospital pharmacies, retail pharmacies, online pharmacies, and other channels. Hospital pharmacies held a dominant market position in 2017, supported by increasing healthcare infrastructure and the growing availability of specialized treatment options. However, online pharmacies are emerging as an important distribution channel due to convenience, expanding e-commerce penetration, and improving consumer access in markets with supportive regulations.

Get Sample PDF Copy: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=39518

Regional Outlook: North America Leads Market Expansion

Geographically, the global CBD hemp oil market covers North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America dominated the global market in 2017, supported by growing awareness of medicinal cannabis, increasing healthcare expenditure, and expanding acceptance of CBD-based products. Regulatory developments and the legalization of cannabis for medicinal or recreational purposes in certain jurisdictions have also contributed to regional market growth.

Asia Pacific is expected to emerge as a promising market, driven by increasing healthcare awareness, expanding pharmaceutical industries, and growing interest in alternative therapies. China held a prominent position in the regional market, while Japan and India offered potential opportunities for future expansion.

Competitive Landscape and Key Market Participants

The global CBD hemp oil market is characterized by the presence of established manufacturers and emerging companies focusing on product innovation, strategic partnerships, cultivation expansion, and geographic diversification.

Major companies operating in the market include ENDOCA, Medical Marijuana, Cannoid, Canopy Growth Corporation, Elixinol Global Limited, Isodiol, NuLeaf Naturals, PharmaHemp, Aphria Inc., and Folium Biosciences.

Strategic collaborations and investments in hemp cultivation are helping manufacturers strengthen their supply chains and improve production capabilities. For instance, in April 2018, Elixinol Global announced an agricultural operations expansion in Colorado, U.S., through its collaboration with Kersey Agricultural Company.

Future Outlook of the CBD Hemp Oil Market

The future of the global CBD hemp oil market will largely depend on regulatory developments, clinical research, product quality standards, and consumer acceptance. Increasing investment in research and development, combined with growing interest in cannabidiol-based pharmaceutical formulations, is expected to create new opportunities for market participants.

However, regulatory uncertainty, inconsistent product standards, and limited clinical evidence for several claimed applications remain important industry challenges. Companies that prioritize product transparency, quality assurance, scientific validation, and regulatory compliance are likely to strengthen their competitive positions.

Overall, increasing demand for plant-based wellness products and continued advancements in cannabinoid research are expected to support the long-term development of the global CBD hemp oil market.

Media Contact:
Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY - 12207, United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

Digital Healthcare Transformation Fuels Global Clinical Analytics Spending

 

The global healthcare industry is undergoing a significant digital transformation, driven by the growing demand for value-based care, improved patient outcomes, and efficient population health management. The transition from traditional, manually operated healthcare systems to digitally managed infrastructure has generated enormous volumes of clinical data. Effectively analyzing this information enables healthcare providers to improve clinical decision-making, minimize hospital readmissions, optimize operational efficiency, and enhance the overall quality of patient care. Consequently, increasing investments in healthcare information technology are creating substantial growth opportunities for the global IT spending on clinical analytics market.

According to historical estimates published by Transparency Market Research (TMR), the global IT spending on clinical analytics market was valued at US$11,650 million in 2015. The market was projected to expand at a compound annual growth rate (CAGR) of 12.3% between 2016 and 2024, reaching approximately US$32,422 million by 2024. This growth outlook highlighted the increasing importance of data-driven healthcare management and the rising adoption of advanced analytics technologies across healthcare organizations.

Integrated Clinical Analytics Solutions to Lead Market Growth

Based on platform, the global IT spending on clinical analytics market is categorized into stand-alone and integrated solutions. Integrated clinical analytics solutions held the leading revenue share in 2015 and were anticipated to maintain their dominance throughout the forecast period.

The integrated segment was projected to register a CAGR of 13.1% between 2016 and 2024, compared with 11.0% for stand-alone solutions. By 2024, integrated platforms were expected to account for approximately 63% of global market spending.

The growing preference for integrated solutions can be attributed to their flexibility and ability to connect with existing healthcare information systems, particularly electronic health records (EHRs). These platforms consolidate information from multiple clinical sources, enabling healthcare professionals to generate actionable insights and make informed decisions. In comparison, stand-alone solutions often face limitations in interoperability and seamless data exchange, restricting their adoption among healthcare providers seeking comprehensive analytics capabilities.

North America Dominates, While Asia Pacific Emerges as a High-Growth Market

Geographically, North America represented the largest regional market for IT spending on clinical analytics. Its leadership was supported by advanced healthcare infrastructure, favorable government initiatives, substantial healthcare IT investments, and widespread adoption of digital health technologies.

According to TMR's historical projections, clinical analytics spending in North America was expected to reach US$5,349 million in 2016 and increase to US$12,110 million by 2024, registering a CAGR of 10.8%.

Meanwhile, Asia Pacific was projected to experience the fastest growth, with spending expected to expand at a CAGR of 16.9% through 2024. Rapid healthcare infrastructure development, increasing digitalization, growing investments in big data technologies, and rising adoption of electronic health records were among the primary factors supporting regional growth.

Japan, China, and India were identified as particularly promising markets, while other developing Asian economies were also expected to create attractive opportunities for clinical analytics vendors.

Get Sample PDF Copy: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16748

Competitive Landscape and Key Market Participants

The global market features several established technology providers and healthcare analytics companies competing through product innovation, strategic partnerships, and technology development. Prominent participants identified in the TMR report include McKesson Corporation, Cerner Corporation, IBM Corporation, Optum, Inc., Allscripts Healthcare Solutions, Inc., Oracle Financial Services Software Limited, CareCloud Corporation, Medical Information Technology, Inc., Hewlett-Packard Enterprise Development LP, and ArborMetrix, Inc.

Digital Healthcare Transformation to Drive Future Opportunities

The growing adoption of EHR systems, artificial intelligence, big data analytics, and cloud-based healthcare platforms continues to strengthen the strategic importance of clinical analytics. Healthcare organizations increasingly recognize that effective data management can reduce administrative inefficiencies, support evidence-based treatment decisions, and improve population health outcomes.

Additionally, the growing emphasis on cost containment and quality-based reimbursement is encouraging hospitals and healthcare networks to invest in advanced analytical capabilities.

Overall, the historical market outlook presented by TMR underscores the significant role of clinical analytics in modernizing healthcare delivery. As healthcare systems continue embracing digital technologies, investments in integrated analytics platforms are positioned to remain an important component of healthcare IT development.

Media Contact:
Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY - 12207, United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

Asia Pacific to Maintain Dominance in the Global Brucellosis Vaccine Market

 

The global brucellosis vaccine market is witnessing steady growth, driven by increasing awareness of zoonotic diseases, expanding livestock vaccination initiatives, and growing investments in veterinary healthcare. Brucellosis, also known as Bang’s disease or contagious abortion, is a bacterial infection that affects cattle, buffaloes, sheep, goats, and other animals, while also posing significant public health risks to humans. The disease can cause reproductive complications, reduced livestock productivity, and substantial economic losses, encouraging governments and market participants to strengthen disease prevention and control measures.

According to market estimates, the global brucellosis vaccine market was valued at US$ 253.1 Mn in 2020 and is projected to reach US$ 387.4 Mn by 2031, expanding at a CAGR of 4% during 2021–2031. Increasing vaccination coverage, supportive government initiatives, and advancements in veterinary vaccine development are expected to create promising opportunities for manufacturers.

Government Support and Healthcare Investments Strengthen Market Prospects

The COVID-19 pandemic highlighted the importance of resilient healthcare infrastructure, reliable supply chains, and financial assistance for healthcare providers. Although the brucellosis vaccine market primarily focuses on animal health, disruptions in logistics, research activities, and healthcare services emphasized the need for stronger operational preparedness across the veterinary healthcare ecosystem.

Market participants are strengthening supply chain networks, improving production capabilities, and exploring government-supported funding opportunities to maintain vaccine availability. Companies are also investing in employee wellness initiatives and digital healthcare solutions to support research collaboration and veterinary consultation services.

The growing integration of telehealth and digital veterinary services is creating additional opportunities to improve disease surveillance, consultation, and preventive healthcare delivery, particularly in underserved rural regions.

Educational and Training Initiatives Support Brucellosis Control in Colombia

Colombia represents an important market for brucellosis prevention due to the presence of the disease across several livestock production systems. Despite ongoing control initiatives, fluctuations in disease prevalence have highlighted the need for comprehensive and sustained intervention strategies.

Companies operating in the Colombia brucellosis vaccine market are emphasizing educational campaigns and training programs to improve disease awareness among livestock owners, veterinary professionals, and rural communities. Traditional smallholders and farmers in low-productivity regions remain important target groups for these initiatives.

Improved awareness of vaccination schedules, disease symptoms, screening procedures, and livestock management practices can support early detection and reduce transmission risks. Greater collaboration between government institutions, veterinary authorities, vaccine manufacturers, and farmers is also expected to strengthen long-term disease eradication efforts.

Get Sample PDF Copy: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=34439

India Emerges as a Promising Growth Market for Vaccine Manufacturers

India offers significant incremental opportunities for brucellosis vaccine manufacturers, supported by its large livestock population and government-led vaccination initiatives. The National Animal Disease Control Programme (NADCP), launched in 2019, has strengthened the country's efforts to control brucellosis and foot-and-mouth disease through large-scale vaccination campaigns.

Under this initiative, vaccination of bovine female calves aged four to eight months is a key component of the brucellosis control strategy. These programs are encouraging manufacturers to expand production capacities and improve vaccine distribution networks.

Since brucellosis can cause abortion, infertility, and reduced reproductive performance in livestock, preventive vaccination plays an important role in protecting animal health and improving farmers' economic outcomes. Increasing awareness of zoonotic transmission is further encouraging investments in livestock immunization programs.

Research and Development Drive Innovation in Brucellosis Vaccines

Technological advancements in veterinary biotechnology are creating new opportunities for vaccine manufacturers. Companies are expanding research and development capabilities to improve vaccine safety, efficacy, stability, and production efficiency.

Conventional vaccines, including RB51 and S19, remain important components of brucellosis prevention strategies. Meanwhile, research into DNA, subunit, vector-based, and recombinant vaccines is supporting the development of potential next-generation solutions.

Preclinical research involving animal models, including guinea pigs, helps researchers evaluate immune responses, protection levels, dosage requirements, and administration methods. Such studies can contribute to the development of improved vaccine candidates, although further testing and regulatory evaluation are essential before human applications can be considered.

Asia Pacific Dominates the Global Brucellosis Vaccine Market

Asia Pacific accounted for the largest share of the global brucellosis vaccine market in 2020, and its dominance is anticipated to continue throughout the forecast period. The region's substantial livestock population, increasing disease awareness, and expanding government vaccination programs are major growth drivers.

China and India are expected to remain important markets as manufacturers pursue product launches, strategic partnerships, distribution agreements, and geographical expansion. North America and Europe also represent established markets, while Latin America and the Middle East & Africa offer opportunities through improved veterinary healthcare infrastructure and disease-control initiatives.

Competitive Landscape and Future Market Opportunities

Leading companies operating in the global brucellosis vaccine market include Merck Animal Health, Ceva Santé Animale, CZ Vaccines, Colorado Serum Company, Indian Immunologicals Ltd., Hester Biosciences Limited, Veterinary Technologies Corporation, Fivet Animal Health, Jordan Bio-industries Center, and Laboratories Tornel.

Market participants are focusing on production expansion, research investments, strategic collaborations, and distribution network development to strengthen their competitive positions.

Overall, rising livestock vaccination coverage, government-backed disease prevention programs, and advancements in veterinary biotechnology are expected to support the steady expansion of the global brucellosis vaccine market through 2031. Manufacturers that prioritize affordable vaccines, reliable supply chains, and stronger collaboration with veterinary stakeholders are likely to benefit from emerging opportunities across developing and established markets.

Media Contact:
Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY - 12207, United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453